AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01841489
Drug: Treatment F
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine
Trial: NCT01841489
Drug: Treatment J
RxNorm normalized name: SALICYLIC ACID 2 g in 151 mL TOPICAL GEL [Clear Blemish Treatment Jafra]
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
Trial: NCT04594668
Drug: Senicapoc
RxNorm normalized name: Senicapoc
DrugBank: Senicapoc (DB06280)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention will consist of 50 mg enteral senicapoc administered as soon as possible after randomization and again after 24 hours
Trial: NCT00405236
Drug: tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00622375
Drug: mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: encapsulated mesalamine granules
Trial: NCT03329846
Drug: BMS-986205
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: specified dose on specified day
Trial: NCT01144091
Drug: pentoxyphylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
Trial: NCT01144091
Drug: pentoxiphylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
Trial: NCT00446641
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cilostazol 100mg twice a day for 4 weeks
Trial: NCT00109824
Drug: decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00109824
Drug: valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01817023
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 100mg/m2 was delivered at d1,d22 and d43 to the CCRT group patients during radiotherapy.
Trial: NCT02949726
Drug: Indocyanine Green (ICG)
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function.
Trial: NCT00424320
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02174991
Drug: Rho-Kinase Inhibitor (AR-12286)
RxNorm normalized name: VEGFR 2 Kinase inhibitor I
DrugBank: VEGFR 2 Kinase inhibitor I (DB17061)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02968368
Drug: Ferric maltol
RxNorm normalized name: Ferric Maltol
DrugBank: Ferric maltol (DB15598)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00324506
Drug: Mycophenolate Mofetil (CellCept)
RxNorm normalized name: MYCOPHENOLATE MOFETIL (CELLCEPT) 500MG TAB
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01544140
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral syrup 7.5 mg, single dose
Trial: NCT01544140
Drug: vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets, 800 mg, single dose
Trial: NCT03820908
Drug: Bisantrene
RxNorm normalized name: Bisantrene
DrugBank: Bisantrene (DB17247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.
Trial: NCT02027272
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
Trial: NCT03527186
Drug: Risperidone ISM® 100 mg
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg of risperidone ISM® administered every 4 weeks
Trial: NCT00449813
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg Pantoprazole
Trial: NCT04612894
Drug: Camrelizumab and Apatinib
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive Camrelizumab and Apatinib for at least two cycles of neoadjuvant treatment
Trial: NCT00143689
Drug: lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See Detailed Description.
Trial: NCT01289119
Drug: Alogliptin
RxNorm normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin tablets
Trial: NCT01289119
Drug: Placebo to alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin placebo-matching tablets.
Trial: NCT01318408
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Titration of Keppra will start at 250 mg by mouth twice daily for three days. Then 500 mg by mouth twice daily for three days. Then 750 mg by mouth twice daily for the duration of the study, or for as long as treatment is necessary. This titration schedule is subject to change based on subject's tolerability.
Trial: NCT00377858
Drug: Insulin lispro mid mixture (MM)
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks
Trial: NCT00377858
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks
Trial: NCT04672317
Drug: Immunotherapy combined with chemotherapy
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy.~Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy~Other Names:~• anti-PD-1 monoclonal antibody Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible.~Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy
Trial: NCT00991939
Drug: Dexamethasone USP Micronized
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose for dexamethasone is 30 mg/day for patients \< 60 kg and 40 mg/day for patients \> 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.
Trial: NCT00991939
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients \> 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients \< 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
Trial: NCT00714415
Drug: BeneFIX
RxNorm normalized name: BeneFIX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Trial: NCT01289119
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Stable metformin dose
Trial: NCT01289119
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stable pioglitazone dose
Trial: NCT01934868
Drug: Epidural Steroid Injection
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space. The injectant solution will be comprised of 80mg methylprednisolone combined with 10mg (2cc) 0.5% bupivicaine. The resulting 4cc will be diluted with another 4cc of normal saline giving a total volume of 8cc. A loss of resistance technique will be used and radiocontrast dye will be injected to verify the placement of the needle prior to injecting the steroid solution.
Trial: NCT01498770
Drug: Asenapine
RxNorm normalized name: Asenapine
DrugBank: Asenapine (DB06216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asenapine prescribed as recorded in the CPRD in the UK
Trial: NCT01498770
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole prescribed as recorded in the CPRD in the UK
Trial: NCT01498770
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine prescribed as recorded in the CPRD in the UK
Trial: NCT01498770
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone prescribed as recorded in the CPRD in the UK
Trial: NCT01498770
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine prescribed as recorded in the CPRD in the UK
Trial: NCT01498770
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ziprasidone prescribed as recorded in the CPRD in the UK
Trial: NCT01498770
Drug: Iloperidone
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloperidone prescribed as recorded in the CPRD in the UK
Trial: NCT02414919
Drug: Mirena (Levonorgestrel IUS, BAY86-5028)
RxNorm normalized name: levonorgestrel Intrauterine System [Mirena]
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel-releasing intrauterine device 20 mcg/day
Trial: NCT01498770
Drug: Paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Paliperidone prescribed as recorded in the CPRD in the UK
Trial: NCT01498770
Drug: Lurasidone
RxNorm normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lurasidone prescribed as recorded in the CPRD in the UK
Trial: NCT01498770
Drug: Clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine prescribed as recorded in the CPRD in the UK
Trial: NCT01498770
Drug: Amisulpride
RxNorm normalized name: Amisulpride
DrugBank: Amisulpride (DB06288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amisulpride prescribed as recorded in the CPRD in the UK
Trial: NCT01498770
Drug: Sertindole
RxNorm normalized name: sertindole
DrugBank: Sertindole (DB06144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole prescribed as recorded in the CPRD in the UK
Trial: NCT01498770
Drug: Zotepine
RxNorm normalized name: zotepine
DrugBank: Zotepine (DB09225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotepine prescribed as recorded in the CPRD in the UK
Trial: NCT00877760
Drug: pegylated interferon a-2a
RxNorm normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 μg, once per week s.c. for 24 weeks
Trial: NCT00877760
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg once daily per os, either 72 weeks or 96 weeks
Trial: NCT02278861
Drug: Sunscreen FPS 60
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
Trial: NCT04270708
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with Autism will be treated with intranasal Dexmedetomidine as a sedative for EEG
Trial: NCT04270708
Drug: Triclofos 100 MG/ML
RxNorm normalized name: triclofos 100 MG/ML
DrugBank: Triclofos (DB06753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with Autism will be treated with oral Triclofos as a sedative for EEG
Trial: NCT02510534
Drug: Menopur 150 international units
RxNorm normalized name: follicle stimulating hormone
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Menopur 150 international units given x 1 dose
Trial: NCT02510534
Drug: Endometrin 100 mg
RxNorm normalized name: Endometrin 100 MG Vaginal Insert
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Endometrin 100mg twice daily x 14 days
Trial: NCT02389192
Drug: ZMAPP
RxNorm normalized name: Zmapp component c4g7
DrugBank: Larcaviximab (DB17775)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
Trial: NCT00612755
Drug: Peginterferon alfa-2a + ribavirin
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a 180 mcg/week ribavirin 1000-1200 mg/day during 24 weeks
Trial: NCT05467384
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg/day in two divided doses
Trial: NCT04233203
Drug: Insulin Faster Aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Currently receiving Faster Aspart during 3 or more months.
Trial: NCT02598440
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants wil receive once-weekly oral alendronate (70 mg tablet)
Trial: NCT01729819
Drug: Tolterodine tartrate extended release capsules
RxNorm normalized name: tolterodine tartrate Extended Release Oral Capsule
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01729819
Drug: Desmopressin orally disintegrating tablets
RxNorm normalized name: desmopressin Oral Tablet
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02393937
Drug: Reference: Metronidazole Gel 1%
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants are assigned to one of three groups in parallel for the duration of the study
Trial: NCT02393937
Drug: Test: Metronidazole Gel 1%
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants are assigned to one of three groups in parallel for the duration of the study
Trial: NCT00053014
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00053014
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00584779
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLcr:14-5 mL/min
Trial: NCT01450761
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01450761
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01450761
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00584779
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLcr: 29-15 mL/min
Trial: NCT00584779
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hemodialysis
Trial: NCT00584779
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CLcr: 29-30 mL/min
Trial: NCT02942693
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib will be used as induction therapy in experimental arm.
Trial: NCT01801774
Drug: Subtenon 20-mg triamcinolone injection
RxNorm normalized name: triamcinolone hexacetonide 20 MG/ML
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment arm will receive single subtenon 20-mg triamcinolone with gentamicin injection after uneventful phacoemulsification. 0.3% Tobramycin eye drop will be given to treatment arm for 28 days to blind the patient.
Trial: NCT01784250
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 150 mcg tablet single dose, to receive by mouth one hour before surgery
Trial: NCT01784250
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol 40 mg tablet single dose, to receive by mouth one hour before surgery
Trial: NCT00744731
Drug: carisbamate
RxNorm normalized name: carisbamate
DrugBank: Carisbamate (DB12338)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day to 1,200 mg per day
Trial: NCT00794859
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg twice daily
Trial: NCT00488059
Drug: enfuvirtide [Fuzeon]
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mg SC twice daily
Trial: NCT00516503
Drug: baclofen/amitriptyline/ketamine gel
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied topically
Trial: NCT00488059
Drug: Integrase inhibitor
RxNorm normalized name: Integrase inhibitors
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00488059
Drug: enfuvirtide [Fuzeon]
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 mg SC once daily
Trial: NCT00943410
Drug: Herceptin
RxNorm normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy
Trial: NCT01378091
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Supplied as 5 mg and 25 mg capsules.~The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day.
Trial: NCT01378091
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks.
Trial: NCT00061893
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children \< 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
Trial: NCT01378091
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.~5 mg BID daily.